Apellis Pharmaceuticals Inc
(NAS:APLS)
$
27.44
-5.56 (-16.85%)
Market Cap: 3.41 Bil
Enterprise Value: 3.49 Bil
PE Ratio: 0
PB Ratio: 14.12
GF Score: 39/100 
Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020 / 05:20PM GMT
Release Date Price:
$30.45
(-3.64%)
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst
Good afternoon. I'm Andrea Tan from the biotechnology team at Goldman Sachs, and it's my pleasure to host a fireside chat with Apellis management team. With us, we have Cedric Francois, Co-Founder and CEO; Adam Townsend, Chief Commercial Officer; and Tim Sullivan, Chief Financial Officer. Thanks so much for joining us today.
Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director
Thank you so much, Andrea.
Questions & Answers
Andrea R. Tan;Cedric Francois
Goldman Sachs Group, Inc., Research Division - Research Analyst;Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director<
Great. So maybe to start, just as a high level overview. If you could provide one of the complement cascade and why targeting C3 is so important? And then maybe provide some thoughts on how to think about that in the context of competitors who are looking at C5 inhibitors?
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers